Brinton Pharmaceuticals: Financial Breakdown
Decoding financial health metrics of Brinton Pharmaceuticals
Total Revenue₹18.8 Cr+3%Prev. FY
Total Expenses₹27.5 Cr+-1%Prev. FY
Profit After Tax₹-8.7 Cr+7%Prev. FY
Total Assets₹7.2 Cr+0%Prev. FY
Net Profit Margin-0.5%9%Prev. FY
FAQs on Financials of Brinton Pharmaceuticals
No. In FY24, Brinton Pharmaceuticals reported a net loss of ₹8.7 Cr+, so it was not profitable.
Brinton Pharmaceuticals's revenue grew 3.5% year-on-year, from ₹18.2 Cr+ in FY23 to ₹18.8 Cr+ in FY24.
Brinton Pharmaceuticals's estimated EBITDA for FY24 was ₹-3.2 Cr+, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY24, Brinton Pharmaceuticals posted revenue of ₹18.8 Cr+ (up 3.5% YoY) and a net loss of ₹8.7 Cr+. Explore the full financials of Brinton Pharmaceuticals here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links